Cancer Tumour Profiling Market Size, Share, Growth, Trends, and Global Industry Analysis: By Cancer Type (Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Melanoma Cancer, Other Cancer), By technique (Genomics, Proteomics, Metabolomics, Epigenetics), By Application (Research, Biomarker Discovery, Personalized Medicine, Clinical Application, Diagnostics, Prognostics, Screening, Others) and Region Forecast 2020-2031

Cancer Tumor Profiling Market size was valued at US$ 12,806.1 million in 2024 and is expected to reach US$ 25,760.6 million by 2031, growing at a significant CAGR of 10.2% from 2025-2031. Cancer/tumour profiling gives information about the genes that cause cancer, which can lead to useful insights into the cancer mechanism. Cancer profiling has the potential to be useful not just in common cancers like lymphoma and breast cancer, but also in molecular profiling of lung cancer, prostate cancer, and acute leukaemia. Cancer profiling plays an important role in molecular diagnostics, as a better understanding of cancer tumours allows clinicians to make proper therapeutic decisions and minimize "over-treatment" of cancer patients.

The global market is being driven by oncologists' increasing demand for cancer profiling methods to diagnose or treat malignancies, as well as forecast response to targeted therapies. Furthermore, the increasing acceptance of cancer biomarkers for tumour profiling, the global increase in cancer incidence, and the growing usage of next-generation sequencing techniques for cancer profiling all contribute to market expansion. However, substantial monetary investments in biomarker development, as well as a scarcity of experienced specialists or oncologists that specialize in tumour profiling, impede market expansion.

Key Developments:

• In January 2025, Predictive Oncology Inc., a leader in AI-driven drug discovery, announced plans to launch its validated ChemoFx® drug response assay in Europe and expand its U.S. availability. Initially focused on ovarian and other gynecological cancers, this tumor profiling assay helps guide personalized treatment decisions. Over time, it may also be used for other major tumor types, supporting more precise and effective cancer therapy.
• In May 2024, Foundation Medicine, Inc. launched FoundationOne®RNA in the U.S. as a tissue-based RNA sequencing test for clinical use. Covering 318 genes, it detects cancer-related fusions across all solid tumors, including NSCLC, pancreatic, and thyroid cancers. Initially available for research in 2023, this launch supports more precise, personalized cancer treatment decisions.
• In June 2023, Quest Diagnostics purchased Haystack Oncology Inc., an early-stage cancer diagnostics startup, for $450 million. This acquisition is intended to strengthen Quest Diagnostics' research and development capabilities, boost market share in cancer diagnostics, and broaden access to liquid biopsy technology.
• In September 2022, Thermo Fisher Scientific introduced the "Oncomine Dx Express Test" and "Oncomine Reporter Dx" alongside the "Ion Torrent Dx System." These CE-IVD (IVDD) tests are intended to allow clinical labs to provide clinically meaningful biomarker results in a single day, hence expanding the company's precision oncology biomarker testing capabilities.

Cancer Tumour Profiling Market Segmentation:

Based on the cancer type:

• Breast Cancer
• Lung Cancer
• Colorectal Cancer
• Prostate Cancer
• Melanoma Cancer
• Other Cancer

Among the various cancer types, breast cancer stands out as the leading segment driving the growth of the Cancer Tumor Profiling Market. Breast cancer remains one of the most prevalent cancers globally, with rising incidence rates and increasing awareness fueling demand for advanced diagnostic tools. Tumor profiling plays a critical role in breast cancer management by identifying hormone receptor status, HER2 expression, and other genetic mutations, which are essential for selecting targeted therapies and predicting treatment responses. As personalized medicine becomes a standard approach in breast cancer care, the need for precise and comprehensive tumor profiling continues to grow rapidly, solidifying its dominant position in the market.

Based on the technique:

• Genomics
• Proteomics
• Metabolomics
• Epigenetics

Among the different techniques, genomics stands as the leading segment driving the Cancer Tumor Profiling Market forward. Genomic profiling provides detailed insights into the genetic mutations and alterations that drive cancer development and progression. By decoding a tumor’s DNA, clinicians can identify actionable mutations, select targeted therapies, and predict treatment outcomes more accurately. The widespread adoption of next-generation sequencing (NGS) technologies has made genomic analysis faster, more comprehensive, and increasingly cost-effective. As precision oncology becomes the standard of care, the demand for genomic profiling continues to rise, allowing oncologists to tailor treatment strategies to each patient’s unique genetic makeup. This strong clinical value has firmly established genomics as the dominant force within the market.

Based on the application:

• Research
• Biomarker Discovery
• Personalized Medicine
• Clinical Application
• Diagnostics
• Prognostics
• Screening
• Others

Among the different applications, personalized medicine is the leading segment driving the Cancer Tumor Profiling Market. Personalized medicine relies heavily on tumor profiling to tailor treatments to each patient’s unique genetic and molecular characteristics. By understanding specific mutations and biomarker expressions, oncologists can select therapies that are more effective and have fewer side effects, ultimately improving patient outcomes and survival rates. The increasing global emphasis on precision oncology, along with advancements in molecular diagnostics and targeted therapies, has fueled the rapid adoption of personalized medicine in cancer treatment. As patients and healthcare providers demand more customized approaches, personalized medicine continues to dominate the market, reinforcing its critical role in shaping the future of cancer care.